Sept 26 (Reuters) - Pasithea Therapeutics Corp :
* PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY, TOLERABILITY, PHARMACOKINETIC $(PK)$, AND PRELIMINARY EFFICACY DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER
* PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON CANCER ACHIEVES PROLONGED STABLE DISEASE
* PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE EVENTS OR DOSE-LIMITING TOXICITIES OBSERVED
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。